Search Within

Joachim Yahalom

  1. "Heiko Schoder"
Formats
  1. Meeting Abstract (28)
  2. Journal Article (20)
  3. Research Letter (2)
Groups
  1. Molecular Imaging and Therapy Service (50)
  2. Radiation Oncology, Department of (50)
  3. Radiology, Department of (50)
  4. Survivorship Research (50)
  5. Department of Medicine (44)
  6. Center for Hematologic Malignancies (43)

More Groups

People
  1. Heiko Schoder (50)
  2. Maria Palomba (36)
  3. Ariela Noy (34)
  4. Alison Moskowitz (33)
  5. Andrew Zelenetz (32)
  6. Paul Hamlin (32)

More People

Years
  1. 2025 (1)
  2. 2024 (5)
  3. 2023 (10)
  4. 2022 (4)
  5. 2021 (5)
  6. 2020 (3)

More Years

Publications
  1. Blood (19)
  2. Hematological Oncology (6)
  3. International Journal of Radiation Oncology, Biology, Physics (6)
  4. Journal of Clinical Oncology (4)
  5. Blood Advances (2)
  6. Blood Cancer Journal (2)

More Publications

Publishers
  1. American Society of Hematology (21)
  2. Elsevier Inc. (7)
  3. Wiley Blackwell (7)
  4. American Society of Clinical Oncology (4)
  5. Ferrata Storti Foundation (2)
  6. Nature Publishing Group (2)

More Publishers

Results (50)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A pilot study of brentuximab vedotin combined with AVD chemotherapy and radiotherapy in patients with newly diagnosed early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L. E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S.; Drill, E.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Uptake of [(18)F]fluorodeoxyglucose in initial positron-emission tomography predicts survival in MALT lymphoma
    Journal Article

    Qi, S.; Huang, M. Y.; Yang, Y.; Schöder, H.; Teckie, S.; Noy, A.; Chau, K.; Yahalom, J.
    Blood Advances (2018)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Chen, R. W.; Constine, L. S.; Courtien, A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Solitary extramedullary plasmacytoma of the cricoid cartilage-case report
    Journal Article

    Krebs, S.; Ganly, I.; Ghossein, R.; Yang, J.; Yahalom, J.; Schöder, H.
    Frontiers in Oncology (2017)

    Fulltext@MSK | Save
  • Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Cadzin, B. R.; Fox, S. Y.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Chen, R.; Constine, L. S.; Courtien, A. I.; Dandapani, S. V.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • PET-adapted therapy with brentuximab vedotin and augmented ICE for relapsed/refractory Hodgkin lymphoma - Lack of Improvement with 3 versus 2 cycles of weekly brentuximab vedotin
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Yahalom, J.; Schöder, H.; Barr, P. M.; Caron, P.; Chiu, A.; Constine, L. S.; Drullinsky, P.; Friedberg, J. W.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • TARC predicts PET-normalization and event free surival in relapsed/refractory Hodgkin lymphoma patients treated with brentuximab vedotin
    Meeting Abstract

    Moskowitz, A. J.; Cho, S.; Fleisher, M.; Woo, K. M.; Zhang, Z. G.; Fox, S.; McCall, S. J.; Schoder, H.; Yahalom, J.; Moskowitz, C. H.
    Blood (2015)

    Fulltext@MSK | Save